Calidi Biotherapeutics, Inc. (CLDI) Misses Q2 EPS by 121c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts CLDI Hot Sheet
Join SI Premium – FREE
Calidi Biotherapeutics, Inc. (NYSE: CLDI) reported Q2 EPS of ($1.40), $1.21 worse than the analyst estimate of ($0.19).
For earnings history and earnings-related data on Calidi Biotherapeutics, Inc. (CLDI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Humana soars, Alignment Healthcare sinks on Medicare rating changes
- Nomura/Instinet Downgrades LG Chem Ltd (051910:KS) (LGCLF) to Neutral
- Morgan Stanley Starts Lotus Bakeries (LOTB:BB) at Equalweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
